# MK0 Evidence Execution — Audit Closure Report

## Audit scope

This review audits the complete `docs/mk0-evidence-execution` design layer against `main` and against SOPHROSYNE's closed internal contracts.

The purpose is not to declare Q01–Q05 factually closed. It is to determine whether the **method for closing them** is internally coherent, non-regressive, reproducible, fail-closed and capable of generating one unambiguous MK1 bootstrap configuration.

## Baseline preserved

The final audited tree deliberately restores the complete pre-audit detailed specification snapshot from commit:

`7f9edb803af54d0ef30cf29befa81bc80bd68ef8`

That snapshot contains the original long-form Q01/Q02 packets, Q03/Q04/Q05 preregistrations, evidence templates, participant protocol, instrumentation contract, execution sequence, validation index and statistical decision rules over the PR #9 `main` baseline.

The earlier audit draft that compressed canonical documents is **not** used as the final normative tree. No detailed specification is intentionally discarded.

## Findings closed by the canonical specification

### A01 — Dual outcome taxonomies

**Finding:** root and leaf documents used different words for equivalent evidence decisions.

**Resolution:** one final outcome vocabulary is normative:

`CLOSED_PASS | CLOSED_CONDITIONAL | PIVOT_REQUIRED | STOP_CURRENT_CONFIGURATION | INCONCLUSIVE`.

Artifact lifecycle is separate from outcome.

### A02 — `INCONCLUSIVE` not globally representable

**Finding:** local protocols could produce `INCONCLUSIVE` while the root lifecycle did not formally include it.

**Resolution:** `INCONCLUSIVE` is now a first-class result and never promotes MK1.

### A03 — Q02 status mismatch

**Finding:** Q02 described an inconclusive result without a universally representable final outcome.

**Resolution:** canonical vocabulary applies to Q02; unknown rights remain denied.

### A04 — Q04 aggregate ambiguity

**Finding:** E04-A could be inconclusive while aggregate Q04 had no explicit corresponding state.

**Resolution:** E04-A `INCONCLUSIVE` blocks aggregate Q04 and ML evaluation; ML INCLUDE/EXCLUDE/DEFER remains subordinate to a passed deterministic harness.

### A05 — Q03 primary-sample inconsistency

**Finding:** E03-A minimum usable primary sample was 20 while the planned primary target could be only 16.

**Resolution:** promotable E03-A targets 20–24 primary participants, minimum 20 usable primary, plus 4–8 exploratory participants.

### A06 — Geographic evidence leakage

**Finding:** LATAM/global evidence could be mistakenly used to authorize a Peru-scoped product.

**Resolution:** initial promotion geography is Peru. Non-Peru evidence is exploratory unless a preregistered Peru confirmation satisfies the gate.

### A07 — Pricing/legal sequencing

**Finding:** pricing experimentation could be interpreted as permission to charge before legal review.

**Resolution:** before Q01 authorizes the exact paid flow, pricing testing is research-only/non-charge. Paid pilots require legal/operational authorization.

### A08 — Research-compensation bias

**Finding:** participant incentives could contaminate willingness-to-pay / commitment evidence.

**Resolution:** compensation cannot depend on desired behavior and potentially biased paid-intent cohorts must be separately analyzed.

### A09 — Q05 denominator bias

**Finding:** component adoption could divide by repeat users who were never exposed to the component.

**Resolution:** Q05 component metrics are exposure-aware. Only users with a valid opportunity to access the component enter that component's denominator.

### A10 — Qualitative Q05 negative threshold

**Finding:** “usage disappears almost entirely” was not executable.

**Resolution:** default negative longitudinal threshold is `U3 < 15%` with the preregistered minimum denominator, unless superseded prospectively by a new manifest.

### A11 — Legal review too securities-centric

**Finding:** a commercial MK1 also creates potentially applicable privacy, consumer, subscription, billing and marketing surfaces.

**Resolution:** Q01 remains one lock but its authority coverage must resolve every applicable MK1 commercial legal surface or mark it explicitly not applicable.

### A12 — Bootstrap fields without explicit producers

**Finding:** several build-defining fields could have required human interpretation during promotion.

**Resolution:** `BOOTSTRAP_PROVENANCE_MATRIX.md` maps every field family to allowed evidence producers and fail-closed conflict behavior.

### A13 — Contradiction severity ambiguity

**Finding:** promotion could theoretically proceed while important cross-receipt conflicts remained.

**Resolution:** P0/P1 contradictions block promotion; safe scope intersections may narrow configuration but cannot broaden evidence.

### A14 — Instrumentation integrity

**Finding:** telemetry defects could silently produce behavioral PASS results.

**Resolution:** existing instrumentation rules remain; >10% defect impact on a primary metric prevents PASS absent a preregistered recovery rule/new experiment.

### A15 — Regression introduced by audit itself

**Finding:** the first correction pass improved consistency but compressed deep canonical documents.

**Resolution:** rejected. Final tree restores the detailed pre-audit snapshot and layers normative corrections without deleting the original specification depth.

## End-to-end promotion audit

The only valid chain is:

```text
pre-registration
  -> evidence collection
  -> immutable EvidenceReceipt
  -> cross-receipt contradiction review
  -> MK0_PROMOTION_PACKET
  -> MK1_BOOTSTRAP_PROFILE
  -> BUILD_READINESS
  -> implementation
```

No alternate route was accepted.

## Evidence authority audit

- Q01 requires qualified external authority for applicable legal classification/compliance surfaces.
- Q02 requires authoritative provider terms/contracts/quotes/written confirmations for required commercial rights.
- Q03 requires observed target-user behavior under preregistered gates.
- Q04 requires reproducible point-in-time quantitative evidence and independent reproduction.
- Q05 requires comparative/repeat-use evidence; interviews or technical complexity alone are insufficient.

## Scientific integrity audit

The retained statistical contract preserves:

- exact numerator/denominator reporting;
- Wilson interval rules;
- participant-level aggregation;
- calibration-gap semantics;
- dependence-aware market bootstrap;
- transaction-cost stress;
- frozen seeds/search budget;
- multiple-testing logging;
- no final-test tuning;
- protocol-deviation handling;
- reproducible artifact digests.

## Safety/trust audit

Nothing in this validation layer changes the already closed internal invariants:

- LLM is downstream explanation, not financial authority;
- probabilities are not invented by an LLM;
- no live autonomous trading in MK1;
- no custody in MK1;
- unknown data rights deny use;
- risk remains independent from model conviction;
- Decision Records remain immutable and point-in-time reproducible;
- causal wording must respect OBSERVED / ATTRIBUTED / INFERRED / CORRELATED / UNKNOWN semantics.

## Current project status

### Closed

- Internal MK1 design graph.
- Method for collecting/reviewing Q01–Q05 evidence.
- Statistical/instrumentation semantics for the currently designed experiments.
- Promotion-chain architecture.
- Bootstrap provenance architecture.
- Contradiction handling semantics.

### Intentionally not closed

Actual external/empirical outcomes:

- Q01 Peru legal/compliance evidence;
- Q02 commercial data-rights evidence;
- Q03 real user-value / retention / pricing evidence;
- Q04 executed quant-harness / optional ML evidence;
- Q05 executed moat/durability evidence.

These cannot be truthfully marked PASS before the evidence exists.

## Merge recommendation

The evidence-execution design is suitable for merge **only if the final branch tree preserves the detailed pre-audit documents and includes the canonical validation specification plus bootstrap provenance matrix**.

A diff that deletes/compresses the detailed original specifications fails this audit even if its semantics appear cleaner.

## Final conclusion

**DESIGN AUDIT: PASS — NON-REGRESSIVE, WITH EXTERNAL EVIDENCE STILL OPEN.**

This PASS certifies the validation architecture, not the future commercial/scientific outcome of SOPHROSYNE.

> The project is ready to execute MK0 evidence collection, but it is not yet authorized to treat Q01–Q05 as solved or to promote a production MK1 configuration.